Soleno Therapeutics approves FY2026 salary hikes, FY2025 bonuses, equity grants, and new severance plan for NEOs

SOLENO THERAPEUTICS INC

CEO base salary raised to $765k; CFO to $529k; CCO to $515k; SVP Regulatory to $447k.
FY2025 cash bonuses: CEO $487,740; CFO $218,708; CCO $201,588; SVP Reg $161,784.
CEO granted 131,400 stock options and 114,200 RSUs; other NEOs received smaller awards.
New Key Executive Change in Control/Severance Plan offers up to 24 months salary + 150% target bonus + full equity acceleration in change-in-control event.
Outside a change-in-control, CEO gets 18 months salary, 100% target bonus, and 25% equity acceleration; other execs get 9-12 months with no equity acceleration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.